Gilead Sciences Selects Emerald BioStructures for Crystallization Studies of a Novel Membrane Protein Target
January 31, 2012
BAINBRIDGE ISLAND, WA. January 31, 2012. Gilead Sciences, Inc. (Foster City, CA) and Emerald BioStructures, Inc. have launched a collaboration to crystallize a novel integral membrane protein drug target. The structural studies will support Gilead’s efforts to use structural insights to support drug discovery for this challenging class of targets. The project will make use of Emerald’s high throughput crystallization platform and specialized membrane protein crystallization tool set and includes a technology transfer component.
About Emerald BioStructures
Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. Emerald has extensive expertise in the engineered expression, protein production and crystal structure determination of GPCRs and integral membrane proteins. The company operates a high-throughput platform leveraged for fragment-based lead discovery and structure-based drug design. Emerald’s work provides a solid foundation for the discovery of highly selective, efficacious drugs. www.emeraldbiostructures.com
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
Emerald BioStructures Contact:
Emerald BioStructures: Diana Wetmore, VP of Business Development & Alliances (206) 780-8959, dwetmore@embios.com
For Media:
Mary Canady, Comprendia LLC
mcanady@comprendia.com